Table 18 Summary of findings table for treatment with galcanezumab 240 mg compared with no treatment for prevention of chronic migraine

Reduction of monthly migraine days follow up: 3 months

The mean reduction of monthly headache days was −2.7 days

The mean reduction of monthly headache days in the intervention group was 1.9 days lower (2.7 lower to 1.1 lower)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with Galcanezumab 240 mg reduces monthly migraine days slightly compared to placebo.

Reduction of monthly acute treatment days follow up: 3 months

The mean reduction of monthly headache days was −2.2 days

The mean reduction of monthly acute treatment days in the intervention group was 2.0 days lower (2.8 lower to 1.3 lower)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with Galcanezumab 240 mg reduces monthly acute treatment days slightly compared to placebo.

Improvement in functional MIDAS score follow up: 3 months

The mean improvement in functional MIDAS score was −11.5 points

The mean improvement in functional MIDAS score in the intervention group was 5.5 points lower (13.1 lower to 2.1 higher)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with Galcanezumab 240 mg does not improve functional MIDAS score significantly compared to placebo.

At least 50% reduction of monthly migraine days follow up: 3 months

149 per 1000

285 per 1000 (216 to 377)

RR 1.9181 (1.4531 to 2.5321)

⨁⨁⨁◯ MEDIUM^a

Treatment with Galcanezumab 240 mg mg results in at least 50% reduction of monthly headache days compared to placebo.

Serious adverse events follow up: 3 months

7 per 1000

19 per 1000 (5 to 70)

RR 2.6534 (0.7181 to 9.8049)

⨁⨁⨁◯ MEDIUM^a

Treatment with Galcanezumab 240 mg mg results in a possibly unimportant effect on serious adverse event occurrence compared to placebo.

Mortality follow up: 3 months

0 per 1000

0 per 1000 (0 to 0)

not estimable

No deaths were observed with treatment with Galcanezumab 240 mg or placebo